Piper Sandler Boosts Repare Therapeutics (NASDAQ:RPTX) Price Target to $30.00

Repare Therapeutics (NASDAQ:RPTXGet Rating) had its target price boosted by analysts at Piper Sandler from $25.00 to $30.00 in a report released on Thursday, Stock Target Advisor reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s target price indicates a potential upside of 242.86% from the company’s current price.

RPTX has been the topic of a number of other research reports. Zacks Investment Research raised shares of Repare Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, May 12th. Stifel Nicolaus lowered shares of Repare Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 12th. The Goldman Sachs Group initiated coverage on Repare Therapeutics in a research report on Thursday, March 17th. They issued a “buy” rating and a $43.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $54.00 price objective on shares of Repare Therapeutics in a research note on Tuesday, April 12th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Repare Therapeutics currently has an average rating of “Buy” and an average target price of $45.13.

NASDAQ RPTX opened at $8.75 on Thursday. The firm has a market cap of $366.54 million, a price-to-earnings ratio of -2.85 and a beta of 0.93. Repare Therapeutics has a one year low of $8.06 and a one year high of $35.75. The firm has a 50 day simple moving average of $11.12 and a 200-day simple moving average of $15.54.

Repare Therapeutics (NASDAQ:RPTXGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.03. Repare Therapeutics had a negative return on equity of 47.60% and a negative net margin of 1,533.38%. As a group, analysts forecast that Repare Therapeutics will post -3.37 EPS for the current fiscal year.

In related news, major shareholder Bvf Partners L. P/Il purchased 420,000 shares of the firm’s stock in a transaction dated Wednesday, May 18th. The stock was acquired at an average price of $8.50 per share, with a total value of $3,570,000.00. Following the completion of the transaction, the insider now owns 3,350,950 shares of the company’s stock, valued at $28,483,075. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 33.60% of the stock is owned by insiders.

Hedge funds have recently bought and sold shares of the stock. National Bank of Canada FI acquired a new position in Repare Therapeutics in the fourth quarter valued at approximately $43,000. Legal & General Group Plc increased its holdings in shares of Repare Therapeutics by 55.5% in the 4th quarter. Legal & General Group Plc now owns 3,923 shares of the company’s stock worth $83,000 after acquiring an additional 1,400 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in Repare Therapeutics by 9.5% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,580 shares of the company’s stock valued at $165,000 after purchasing an additional 1,002 shares during the period. Virtus ETF Advisers LLC grew its position in Repare Therapeutics by 28.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,355 shares of the company’s stock worth $176,000 after purchasing an additional 1,873 shares during the last quarter. Finally, California State Teachers Retirement System acquired a new stake in shares of Repare Therapeutics in the third quarter valued at approximately $198,000. 89.66% of the stock is currently owned by institutional investors and hedge funds.

Repare Therapeutics Company Profile (Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

Featured Stories

Stock Target Advisor logo

Analyst Recommendations for Repare Therapeutics (NASDAQ:RPTX)

Want More Great Investing Ideas?

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.